Filing Flows

Filing Flows › 8-K events › AbbVie

AbbVie: departure or appointment of directors and officers

Form 8-K filed Nov 2, 2026 · items 5.02

What the filing says

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers On October 28, 2026, Jennifer L.

Read the filing on SEC EDGAR →

What usually followsAcross 39,174 8-Ks reporting Item 5.02 (directors and officers: departures, appointments, pay) in our universe, the stock's median move the next session was −0.1% (typical size ±1.4%, up 48% of the time); over the following 21 sessions, +0.7%. Every item ranked →

What this kind of filing means

Item 5.02 — Departure or appointment of directors and officers. Leadership changes: who leaves, who arrives and on what terms. A sudden CEO or CFO departure without a successor deserves attention.

AbbVie at a glance

Latest quarterQ3 2026
Revenue$17.4B
Revenue Y/Y+10%
Operating margin36.0%
IndustryPharmaceutical Preparations

AbbVie, Q3 2026: revenue $17.4B (+10% year over year), operating margin 36.0%. The chart follows the revenue to costs, profit and cash.

AbbVie: every quarter, Q/Q and Y/Y, holders and guidance →

Other recent ceo changes

Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.